Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07065214

Argon Plasma Treatment for Ovarian Endometrioma Compared to Standard Cystectomy

The study is a prospective, monocentric, randomized controlled, two-armed, pilot-study conducted at Department for Women's Health, Tuebingen, Germany.

In this Post Market Study it will be determined whether and to what extent the two surgical procedures for ovarian endometrioma treatment (standard cystectomy versus APC) may affect the ovarian reserve by comparing changes in serum AMH levels after treatment.

Seventy-two (72) patients who meet all eligibility criteria will undergo surgical procedure. The patients will be randomized into the group with standard cystectomy treatment or with APC treatment. Per group n=36 patients will be treated i.e., 1:1 randomization.

A pre-specified primary endpoint analysis is planned after the last patient has undergo Visit 4 (Follow-up after 6 months) to analyze the primary endpoint.

Screening takes place during the first visit (V1). During the second visit (V2) the participants will receive the ovarian endometriosis treatment procedure either with the APC or the standard cystectomy. Standard procedure (standard cystectomy) will be performed for additional endometriosis lesions. The follow up visits (V3 - V5) will take place after three, six and twelve months. Visit 3 and Visit 4 will take place at the study site and AMH will be measured. Whereas Visit 5 will take place via telemedical contact, i.e. phone call.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Department for Women's Health

Tübingen, Germany, 72076

Location status: Recruiting

Location contact

Bernhard Krämer, Prof. Dr. med.

CONTACT

[email protected]

+49 7071 29 82211

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Indication for surgical endometrioma treatment according to patient symptoms
  • Signed informed consent

Exclusion criteria

  • Expected lack of patient compliance or inability of the patient to understand the purpose of the clinical trial
  • Prior procedures at the ovaries
  • Recurrent endometrioma (patients with recurrent endometriosis outside of the ovar, e.g. peritoneal endometriosis lesions can be included)
  • Pregnant or breastfeeding patients
  • Participation in any other clinical study that could affect the AMH level or pregnancy

Treatment and study plan

APC

Device

For the surgical procedure for ovarian endometrioma treatment APCapplicator will be used

Other names: APC Treatment with APCapplicator

Lap bipolar forceps

Device

For ovarian endometrioma treatment the standard of care treatment will be performed.

Primary outcomes

  1. Concentration of AMH (Anti-Müller hormone) level

    Time frame: Screening Visit 1 (up to -28 days before day 0); Visit 3 (day 0 +3 months +/- 14 days; Visit 4 (day 0 + 6 months +/- 14 days)

    The comparison of patient AMH changes (ΔAMH) before and after surgery (Follow up Visit after 3 and 6 months) with either APC or standard cystectomy (ΔAMH Group 1 versus ΔAMH Group 2).

Study contacts

Contact information is provided by the study sponsor or research team.

Vanessa Steinmetz

CONTACT

[email protected]

+49 70717552850

Sponsors and collaborators

Lead sponsor

Erbe Elektromedizin GmbH

Industry

Registry information

Official study title

Argon Plasma Treatment for Ovarian Endometrioma Compared to Standard Cystectomy: A Prospective Controlled Randomized Pilot Study

Acronym: OVAPLAS

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jul 15, 2025
Registry last updated
Nov 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.